Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mind Medicine (MNMD)
NASDAQ:MNMD
Mind Medicine (MNMD) Stock Price & Analysis
1,043 Followers
MNMD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.41 - $12.22
Previous Close$8.22
Volume1.01M
Average Volume (3M)2.41M
Market Cap
$579.52M
Enterprise Value$493.94M
Total Cash (Recent Filing)$99.70M
Total Debt (Recent Filing)$14.13M
Price to Earnings (P/E)-2.8
Beta1.95
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.94
Shares Outstanding41,334,307
10 Day Avg. Volume1,275,671
30 Day Avg. Volume2,405,550
Standard Deviation1.43
R-Squared0.07
Alpha0.33
Financial Highlights & Ratios
Price to Book (P/B)6.20
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-12.12
Forecast
1Y Price Target
$32.66Price Target Upside297.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Mind Medicine News
PremiumCompany Announcements
MindMed Triumphs in Anxiety Treatment Trials
PremiumCompany Announcements
MindMed Files 8-K Report, Shares Trade on Nasdaq
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsMindMed's MM-120 shows a significant improvement in Generalized Anxiety Disorder symptoms, outperforming standard treatments.
Financial StabilityMindMed's strong cash position ensures continued operations and funds crucial Phase 3 trials into 2026.
Regulatory MilestoneThe FDA's breakthrough status for MM-120 enhances its potential for expedited regulatory support.
Bears Say
Clinical Trial OutcomeThe ADHD study for sub-perceptual MM120 did not meet its primary endpoint, leading to the termination of the program.
Drug Development RisksKey risks include potential failure of MM120 in Phase 3 studies, unexpected safety issues, regulatory setbacks, and competitive pressures.
Financial ForecastPrice target modulated to $35 from $75 due to a recent capital raise and an increase in estimated operating expenses.
---
Ownership Overview
0.00% Insiders
1.42% Mutual Funds
1.41% Other Institutional Investors
97.17% Public Companies and Individual Investors
MNMD FAQ
What was Mind Medicine’s price range in the past 12 months?
Mind Medicine lowest stock price was $2.41 and its highest was $12.22 in the past 12 months.
What is Mind Medicine’s market cap?
Currently, no data Available
When is Mind Medicine’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Mind Medicine’s earnings last quarter?
Currently, no data Available
Is Mind Medicine overvalued?
According to Wall Street analysts Mind Medicine’s price is currently Undervalued.
Does Mind Medicine pay dividends?
Mind Medicine does not currently pay dividends.
What is Mind Medicine’s EPS estimate?
Mind Medicine’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mind Medicine have?
Mind Medicine has 70,500,980 shares outstanding.
What happened to Mind Medicine’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Mind Medicine?
Currently, no hedge funds are holding shares in MNMD
---
Mind Medicine Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$32.66 (297.34% Upside)
$32.66 (297.34% Upside)
Blogger Sentiment
Bullish
MNMD Sentiment 87%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth C$376.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 7.4%
Last 30 Days ▲ 7.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
MNMD Stock 12 Month Forecast
Average Price Target
$32.66
▲(297.34% Upside)
Technical Analysis
Best Analysts Covering MNMD
1 Year
1 Year Success Rate
0/3 ratings generated profit
1 Year Average Return
0.00%
assigned a buy rating 6 days ago
Copying Francois Brisebois's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of 0.00% per trade.
---